Charles Francis Burant, MD, PhD
Dr Robert C and Veronica Atkins Professor of Metabolism
Professor of Internal Medicine
Professor of Molecular and Integrative Physiology
Director of the A Alfred Taubman Medical Research Institute at Michigan Medicine
Professor of Nutritional Sciences
Internal Medicine
6903 Brehm Tower 1000 Wall St.
Ann Arbor, MI 48109
[email protected]

Available to mentor
Charles Francis Burant, MD, PhD
Professor
  • About
  • Qualifications
  • Center Memberships
  • Research Overview
  • Recent Publications
    • About

    Charles Burant is professor of Internal Medicine, Section of Metabolism, Endocrinology, and Diabetes. He holds the Robert C. and Veronica Atkins Professor of Metabolism endowed chair. His clinical interests are in the care of patients with obesity, type 2 diabetes, and related conditions. Burant is the Director of the Taubman Institute, leading its mission to support the careers of clinicians who performing research as a primary focus of their academic activities as well as supporting a diverse number of muli-investigator translational research programs. He is the founding director of Director of the Michigan Metabolomics Core which provides the research community with access to cutting edge technology and informatics support to integrate metabolite profiling into their research program.

    Qualifications
    • Endocrinology
      University of Chicago, Chicago, 1991
    • Internal Medicine
      University of California, San Francisco, San Francisco, 1989
    • PhD
      Medical University of South Carolina, Charleston, 1987
    • MD
      Medical University of South Carolina, Charleston, 1987
    • MS
      University of Wisconsin, Madison, 1981
    • BS
      University of Wisconsin, Madison, 1979
    Center Memberships
    • Center Member
      Center for Computational Medicine and Bioinformatics
    • Center Member
      Taubman Institute
    • Center Member
      Samuel and Jean Frankel Cardiovascular Center
    • Center Member
      Caswell Diabetes Institute
    • Center Member
      Center for Cell Plasticity and Organ Design
    Research Overview

    Burant's personal research program centers on the interaction between genetically driven traits such as intrinsic oxidative capacity and environmental factors such as nutrients and exercise, in the development and treatment of insulin resistance, obesity and β-cell failure in both man and in animal models. Burant is a specific interest in intermediary metabolism and his laboratory combines genetics, epigenetics, metabolomics, and transcriptomics to understand the causes and phenotypic manifestation of cardiometabolic disease.

    Recent Publications See All Publications
    • Journal Article
      Early pregnancy serum PFAS are associated with alterations in the maternal lipidome.
      Rabotnick MH, Haidari A, Dolinoy DC, Meijer JL, Harris SM, Burant CF, Padmanabhan V, Goodrich JM. Environ Res, 2024 Oct 18; 263 (Pt 3): 120183 DOI:10.1016/j.envres.2024.120183
      PMID: 39426451
    • Journal Article
      The impact of exercise on gene regulation in association with complex trait genetics.
      Vetr NG, Gay NR, MoTrPAC Study Group , Montgomery SB. Nat Commun, 2024 May 1; 15 (1): 3346 DOI:10.1038/s41467-024-45966-w
      PMID: 38693125
    • Proceeding / Abstract / Poster
      12436 Madelung’S Multiple Symmetric Lipomatosis: A New Indication For Leptin Pathway Activation?
      de Freitas MCF, Gomes AD, Schill R, Obua BM, Kaba D, Verma S, Guler MC, Gilio D, Hoose K, Soni T, Chun T-H, Burant CF, Cederna P, MacDougald OA, Oral EA. Journal of the Endocrine Society, 2024 Jun 1; 8 (Supplement_1): bvae163.004 - bvae163.004. DOI:10.1210/jendso/bvae163.004
    • Additional Scholarship
      Data from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways
      Venneti S, Kawakibi AR, Ji S, Waszak SM, Sweha SR, Mota M, Pun M, Deogharkar A, Chung C, Tarapore RS, Ramage S, Chi A, Wen PY, Arrillaga-Romany I, Batchelor TT, Butowski NA, Sumrall A, Shonka N, Harrison RA, de Groot J, Mehta M, Hall MD, Daghistani D, Cloughesy TF, Ellingson BM, Beccaria K, Varlet P, Kim MM, Umemura Y, Garton H, Franson A, Schwartz J, Jain R, Kachman M, Baum H, Burant CF, Mottl SL, Cartaxo RT, John V, Messinger D, Qin T, Peterson E, Sajjakulnukit P, Ravi K, Waugh A, Walling D, Ding Y, Xia Z, Schwendeman A, Hawes D, Yang F, Judkins AR, Wahl D, Lyssiotis CA, de la Nava D, Alonso MM, Eze A, Spitzer J, Schmidt SV, Duchatel RJ, Dun MD, Cain JE, Jiang L, Stopka SA, Baquer G, Regan MS, Filbin MG, Agar NYR, Zhao L, Kumar-Sinha C, Mody R, Chinnaiyan A, Kurokawa R, Pratt D, Yadav VN, Grill J, Kline C, Mueller S, Resnick A, Nazarian J, Allen JE, Odia Y, Gardner SL, Koschmann C. 2024 Sep 16; DOI:10.1158/2159-8290.c.6908476
    • Additional Scholarship
      Data from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways
      Venneti S, Kawakibi AR, Ji S, Waszak SM, Sweha SR, Mota M, Pun M, Deogharkar A, Chung C, Tarapore RS, Ramage S, Chi A, Wen PY, Arrillaga-Romany I, Batchelor TT, Butowski NA, Sumrall A, Shonka N, Harrison RA, de Groot J, Mehta M, Hall MD, Daghistani D, Cloughesy TF, Ellingson BM, Beccaria K, Varlet P, Kim MM, Umemura Y, Garton H, Franson A, Schwartz J, Jain R, Kachman M, Baum H, Burant CF, Mottl SL, Cartaxo RT, John V, Messinger D, Qin T, Peterson E, Sajjakulnukit P, Ravi K, Waugh A, Walling D, Ding Y, Xia Z, Schwendeman A, Hawes D, Yang F, Judkins AR, Wahl D, Lyssiotis CA, de la Nava D, Alonso MM, Eze A, Spitzer J, Schmidt SV, Duchatel RJ, Dun MD, Cain JE, Jiang L, Stopka SA, Baquer G, Regan MS, Filbin MG, Agar NYR, Zhao L, Kumar-Sinha C, Mody R, Chinnaiyan A, Kurokawa R, Pratt D, Yadav VN, Grill J, Kline C, Mueller S, Resnick A, Nazarian J, Allen JE, Odia Y, Gardner SL, Koschmann C. 2024 Sep 16; DOI:10.1158/2159-8290.c.6908476.v2
    • Additional Scholarship
      Supplementary Data S1 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways
      Venneti S, Kawakibi AR, Ji S, Waszak SM, Sweha SR, Mota M, Pun M, Deogharkar A, Chung C, Tarapore RS, Ramage S, Chi A, Wen PY, Arrillaga-Romany I, Batchelor TT, Butowski NA, Sumrall A, Shonka N, Harrison RA, de Groot J, Mehta M, Hall MD, Daghistani D, Cloughesy TF, Ellingson BM, Beccaria K, Varlet P, Kim MM, Umemura Y, Garton H, Franson A, Schwartz J, Jain R, Kachman M, Baum H, Burant CF, Mottl SL, Cartaxo RT, John V, Messinger D, Qin T, Peterson E, Sajjakulnukit P, Ravi K, Waugh A, Walling D, Ding Y, Xia Z, Schwendeman A, Hawes D, Yang F, Judkins AR, Wahl D, Lyssiotis CA, de la Nava D, Alonso MM, Eze A, Spitzer J, Schmidt SV, Duchatel RJ, Dun MD, Cain JE, Jiang L, Stopka SA, Baquer G, Regan MS, Filbin MG, Agar NYR, Zhao L, Kumar-Sinha C, Mody R, Chinnaiyan A, Kurokawa R, Pratt D, Yadav VN, Grill J, Kline C, Mueller S, Resnick A, Nazarian J, Allen JE, Odia Y, Gardner SL, Koschmann C. 2024 Sep 16; DOI:10.1158/2159-8290.27026282
    • Additional Scholarship
      Supplementary Data S1 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways
      Venneti S, Kawakibi AR, Ji S, Waszak SM, Sweha SR, Mota M, Pun M, Deogharkar A, Chung C, Tarapore RS, Ramage S, Chi A, Wen PY, Arrillaga-Romany I, Batchelor TT, Butowski NA, Sumrall A, Shonka N, Harrison RA, de Groot J, Mehta M, Hall MD, Daghistani D, Cloughesy TF, Ellingson BM, Beccaria K, Varlet P, Kim MM, Umemura Y, Garton H, Franson A, Schwartz J, Jain R, Kachman M, Baum H, Burant CF, Mottl SL, Cartaxo RT, John V, Messinger D, Qin T, Peterson E, Sajjakulnukit P, Ravi K, Waugh A, Walling D, Ding Y, Xia Z, Schwendeman A, Hawes D, Yang F, Judkins AR, Wahl D, Lyssiotis CA, de la Nava D, Alonso MM, Eze A, Spitzer J, Schmidt SV, Duchatel RJ, Dun MD, Cain JE, Jiang L, Stopka SA, Baquer G, Regan MS, Filbin MG, Agar NYR, Zhao L, Kumar-Sinha C, Mody R, Chinnaiyan A, Kurokawa R, Pratt D, Yadav VN, Grill J, Kline C, Mueller S, Resnick A, Nazarian J, Allen JE, Odia Y, Gardner SL, Koschmann C. 2024 Sep 16; DOI:10.1158/2159-8290.27026282.v1
    • Additional Scholarship
      Supplementary Data S2 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways
      Venneti S, Kawakibi AR, Ji S, Waszak SM, Sweha SR, Mota M, Pun M, Deogharkar A, Chung C, Tarapore RS, Ramage S, Chi A, Wen PY, Arrillaga-Romany I, Batchelor TT, Butowski NA, Sumrall A, Shonka N, Harrison RA, de Groot J, Mehta M, Hall MD, Daghistani D, Cloughesy TF, Ellingson BM, Beccaria K, Varlet P, Kim MM, Umemura Y, Garton H, Franson A, Schwartz J, Jain R, Kachman M, Baum H, Burant CF, Mottl SL, Cartaxo RT, John V, Messinger D, Qin T, Peterson E, Sajjakulnukit P, Ravi K, Waugh A, Walling D, Ding Y, Xia Z, Schwendeman A, Hawes D, Yang F, Judkins AR, Wahl D, Lyssiotis CA, de la Nava D, Alonso MM, Eze A, Spitzer J, Schmidt SV, Duchatel RJ, Dun MD, Cain JE, Jiang L, Stopka SA, Baquer G, Regan MS, Filbin MG, Agar NYR, Zhao L, Kumar-Sinha C, Mody R, Chinnaiyan A, Kurokawa R, Pratt D, Yadav VN, Grill J, Kline C, Mueller S, Resnick A, Nazarian J, Allen JE, Odia Y, Gardner SL, Koschmann C. 2024 Sep 16; DOI:10.1158/2159-8290.27026279.v1